FDA Hormone Therapy Risk Management Options Include Narrower Indication
Executive Summary
FDA is considering limiting hormone therapy indications to patients with more severe menopausal symptoms or those at a high risk for osteoporosis, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said Oct. 24
You may also be interested in...
Berlex Climara Pro Triglyceride Effect Is Point Of Difference For HRT Patch
Berlex Labs can highlight Climara Pro's effect on triglycerides as one point of differentiation in marketing the transdermal hormone therapy product
Berlex Climara Pro Triglyceride Effect Is Point Of Difference For HRT Patch
Berlex Labs can highlight Climara Pro's effect on triglycerides as one point of differentiation in marketing the transdermal hormone therapy product
HRT Class Labeling Should Not Cover Topical Estrogens, Pharmacia Says
Topical hormone therapy drugs should be exempt from FDA's proposed estrogen class labeling incorporating safety information from the Women's Health Initiative study, Pharmacia maintained in comments submitted to the agency